Comprehensive Classification of Cell Wall Inhibitors and Protein Synthesis Inhibitors

Overview of Antibacterial Pharmacotherapy

• Antibacterial therapeutic agents are primarily classified according to their mechanism of action and structural molecular features.
• The major physiological targets illustrated in antibacterial pharmacotherapy are:
  • Bacterial cell wall synthesis inhibition.
  • Bacterial protein synthesis inhibition.

Agents Affecting the Cell Wall (Cell Wall Inhibitors)

• Bacterial cell wall inhibitors target the assembly and structural integrity of the peptidoglycan cell wall layer, leading to cell lysis and bacterial death.

$\beta$-Lactam Antibiotics

• Antibiotics containing a core $\beta$-lactam ring that acts by binding to penicillin-binding proteins (PBPs) to inhibit bacterial transpeptidase activity and peptidoglycan cross-linking.

Penicillins

• Amoxicillin: Aminopenicillin providing antimicrobial activity against Gram-positive organisms and select Gram-negative bacilli.
• Ampicillin: Aminopenicillin active against susceptible Gram-positive bacteria and Gram-negative pathogens.
• Dicloxacillin: Penicillinase-resistant isoxazolyl penicillin indicated for penicillinase-producing staphylococci.
• Indanyl carbenicillin: Antipseudomonal carboxypenicillin formulation with Gram-negative efficacy.
• Methicillin: Penicillinase-resistant penicillin traditionally utilized in laboratory susceptibility testing.
• Nafcillin: Penicillinase-resistant penicillin designated for severe staphylococcal infections.
• Oxacillin: Penicillinase-resistant penicillin effective against resistant staphylococcal strains.
• Penicillin G: Parenteral natural penicillin indicated for streptococcal, meningococcal, and treponemal infections.
• Penicillin V: Oral natural penicillin used for mild-to-moderate streptococcal infections.
• Piperacillin: Extended-spectrum antipseudomonal ureidopenicillin active against Pseudomonas aeruginosa.
• Ticarcillin: Antipseudomonal carboxypenicillin utilized for Gram-negative bacillary infections.

Cephalosporins

• Cephalosporins are subdivided into structural and activity generations, extending from Gram-positive focus in early generations to broad Gram-negative utility in later generations.

First Generation Cephalosporins

• Cefadroxil: Oral first-generation cephalosporin for skin, soft tissue, and urinary tract infections.
• Cefazolin: Parenteral first-generation cephalosporin widely utilized for surgical prophylaxis and Gram-positive skin infections.
• Cephalexin: Oral first-generation cephalosporin for outpatient management of Gram-positive and urinary tract infections.

Second Generation Cephalosporins

• Cefador: Second-generation cephalosporin active against susceptible respiratory pathogens.
• Cefprozil: Second-generation cephalosporin indicated for upper and lower respiratory tract infections.
• Cefuroxime: Second-generation cephalosporin active against Gram-negative respiratory pathogens and capable of central nervous system penetration.
• Cefoxitin: Second-generation cephamycin with potent coverage against anaerobic pathogens, including Bacteroides fragilis.

Third Generation Cephalosporins

• Cefdinir: Oral third-generation cephalosporin prescribed for respiratory and soft tissue infections.
• Cefixime: Oral third-generation cephalosporin active against Gram-negative enteric bacilli.
• Cefotaxime: Parenteral third-generation cephalosporin offering broad Gram-negative coverage and central nervous system penetration.
• Ceftazidime: Third-generation cephalosporin possessing extended intrinsic activity against Pseudomonas aeruginosa.
• Ceftibuten: Oral third-generation cephalosporin prescribed for acute otitis media and respiratory exacerbations.
• Ceftizoxime: Parenteral third-generation cephalosporin resistant to degradation by broad-spectrum $\beta$-lactamases.
• Ceftriaxone: Broad-spectrum parenteral third-generation cephalosporin featuring long half-life for once-daily administration in meningitis, pneumonia, and gonorrhea.

Fourth Generation Cephalosporins

• Cefepime: Fourth-generation cephalosporin featuring broad activity against Gram-positive cocci and Pseudomonas aeruginosa, with high resistance to $\beta$-lactamase inactivation.

Carbapenems

• Carbapenems exhibit broad antimicrobial spectra across Gram-positive, Gram-negative, and anaerobic bacterial species.
• Ertapenem: Carbapenem lacking activity against Pseudomonas aeruginosa, administered once daily for community-acquired infections.
• Imipenem/cilastatin*: Combination of imipenem with cilastatin, an inhibitor of renal dehydropeptidase-1 that prevents renal inactivation of imipenem.
• Meropenem: Broad-spectrum carbapenem effective against severe intra-abdominal, nosocomial, and central nervous system infections.

Monobactams

• Monobactams possess a monocyclic $\beta$-lactam structure without a fused second ring.
• Aztreonam: Monobactam selectively active against aerobic Gram-negative bacilli, exhibiting no cross-reactivity in patients with penicillin allergies.

Other Antibiotics Affecting the Cell Wall

• Non-$\beta$-lactam antibacterial agents targeting bacterial cell wall synthesis through alternative pathways or structural binding sites.
• Bacitracin: Peptide antibiotic that inhibits bacterial cell wall synthesis by interfering with lipid carrier pyrophosphatase dephosphorylation.
• Vancomycin: Glycopeptide antibiotic that binds D-alanyl-D-alanine termini of cell wall precursors, preventing peptidoglycan polymerization in Gram-positive bacteria.
• Daptomycin: Cyclic lipopeptide agent that integrates into Gram-positive bacterial cell membranes, causing rapid depolarization and cell death.

$\beta$-Lactamase Inhibitors

• Molecular inhibitors co-administered with $\beta$-lactam antibiotics to prevent inactivation by bacterial $\beta$-lactamase enzymes.
• Clavulanic acid: $\beta$-Lactamase inhibitor formulated in combination with aminopenicillins (e.g., amoxicillin).
• Sulbactam: $\beta$-Lactamase inhibitor paired with ampicillin to restore susceptibility in $\beta$-lactamase-producing organisms.
• Tazobactam: Potent $\beta$-lactamase inhibitor co-formulated with extended-spectrum penicillins (e.g., piperacillin).

Classification of Protein Synthesis Inhibitors

• Protein synthesis inhibitors disrupt bacterial translation by selectively binding to the $30\text{S}$ or $50\text{S}$ ribosomal subunit.

Tetracyclines

• Reversibly bind to the $30\text{S}$ ribosomal subunit, blocking aminoacyl-tRNA attachment to the acceptor site on the mRNA-ribosome complex.
• Demeclocycline: Intermediate-acting tetracycline derivative.
• Doxycycline: Long-acting tetracycline active against atypical respiratory pathogens, rickettsiae, and spirochetes.
• Minocycline: Highly lipophilic tetracycline derivative with broad tissue penetration.
• Tetracycline: Standard short-acting member of the tetracycline group.

Glycylcyclines

• Semi-synthetic tetracycline analogs designed to evade efflux pumps and ribosomal protection resistance mechanisms.
• Tigecycline: Glycylcycline antibiotic active against resistant Gram-positive, Gram-negative, and anaerobic pathogens.

Aminoglycosides

• Bactericidal agents that irreversibly bind to the $30\text{S}$ ribosomal subunit, causing misreading of genetic code and premature protein termination.
• Amikacin: Aminoglycoside resistant to many enzymatic inactivation pathways, reserved for resistant Gram-negative infections.
• Gentamicin: Primary aminoglycoside used for serious systemic Gram-negative bacillary infections.
• Neomycin: Highly potent aminoglycoside restricted largely to topical administration and oral bowel decontamination.
• Streptomycin: Aminoglycoside indicated in tuberculosis treatment combinations and enterococcal endocarditis regimens.
• Tobramycin: Aminoglycoside possessing marked activity against Pseudomonas aeruginosa.

Macrolides and Ketolides

• Agents that bind to the $50\text{S}$ ribosomal subunit, blocking transpeptidation and protein elongation steps.
• Azithromycin: Macrolide antibiotic with long tissue half-life and broad activity against atypical respiratory pathogens.
• Clarithromycin: Macrolide active against respiratory tract pathogens and Helicobacter pylori.
• Erythromycin: Prototypical macrolide active against Gram-positive bacteria and atypical pathogens.
• Telithromycin: Ketolide derivative engineered to maintain activity against macrolide-resistant streptococci.

Chloramphenicol

• Chloramphenicol: Broad-spectrum antibiotic that reversibly binds to the $50\text{S}$ ribosomal subunit to inhibit peptidyl transferase; restricted due to bone marrow toxicity risks.

Clindamycin

• Clindamycin: Lincosamide antibiotic that binds to the $50\text{S}$ ribosomal subunit; displays activity against Gram-positive cocci and anaerobic bacteria.

Quinupristin / Dalfopristin

• Quinupristin / Dalfopristin: Combination streptogramin antibiotic ($30:70$ proportion) that acts synergistically at distinct sites on the $50\text{S}$ ribosomal subunit to inhibit protein synthesis.

Linezolid

• Linezolid: Oxazolidinone antibiotic that binds to the $23\text{S}$ rRNA of the $50\text{S}$ subunit, preventing assembly of the functional $70\text{S}$ initiation complex in resistant Gram-positive organisms.